1. Glypican‐3 antibodies: A new therapeutic target for liver cancer. Issue 2 (15th October 2013) Authors: Feng, Mingqian; Ho, Mitchell Journal: FEBS letters Issue: Volume 588:Issue 2(2014) Page Start: 377 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Frizzled‐Like Cysteine‐Rich Domain in Glypican‐3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice. Issue 4 (24th May 2019) Authors: Li, Na; Wei, Liwen; Liu, Xiaoyu; Bai, Hongjun; Ye, Yvonne; Li, Dan; Li, Nan; Baxa, Ulrich; Wang, Qun; Lv, Ling; Chen, Yun; Feng, Mingqian; Lee, Byungkook; Gao, Wei; Ho, Mitchell Journal: Hepatology Issue: Volume 70:Issue 4(2019) Page Start: 1231 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Engineered Anti‐GPC3 Immunotoxin, HN3‐ABD‐T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention. Issue 5 (27th January 2020) Authors: Fleming, Bryan D.; Urban, Daniel J.; Hall, Matthew D.; Longerich, Thomas; Greten, Tim F.; Pastan, Ira; Ho, Mitchell Journal: Hepatology Issue: Volume 71:Issue 5(2020) Page Start: 1696 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Melanoma-associated B cells are distinct from peripheral blood-derived B cells, and may serve as a source of tumor-targeting antibodies. (7th November 2013) Authors: Abate-Daga, Daniel; Alexander, Theresa A; Arons, Evgeny; Ho, Mitchell; Robbins, Paul F; Rosenberg, Steven A; Morgan, Richard A Journal: Journal for immunotherapy of cancer Issue: Volume 1(2013)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A novel IgM intranasal intervention against SARS-CoV-2. (28th August 2021) Authors: Yerabham, Antony; Ho, Mitchell Journal: Antibody therapeutics Issue: Volume 4:Number 3(2021) Page Start: 171 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel. (April 2015) Authors: Hanaoka, Hirofumi; Nakajima, Takahito; Sato, Kazuhide; Watanabe, Rira; Phung, Yen; Gao, Wei; Harada, Toshiko; Kim, Insook; Paik, Chang H; Choyke, Peter L; Ho, Mitchell; Kobayashi, Hisataka Journal: Nanomedicine Issue: Volume 10:Number 7(2015) Page Start: 1139 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Inaugural Editorial: Searching for Magic Bullets. (20th June 2018) Authors: Ho, Mitchell Journal: Antibody therapeutics Issue: Volume 1:Number 1(2018) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. DNA damaging agent-based antibody-drug conjugates for cancer therapy. (30th August 2018) Authors: Fu, Ying; Ho, Mitchell Journal: Antibody therapeutics Issue: Volume 1:Number 2(2018) Page Start: 43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Isolation of rabbit single domain antibodies to B7-H3 via protein immunization and phage display. (17th February 2020) Authors: Feng, Ruonan; Wang, Ruixue; Hong, Jessica; Dower, Christopher M; Croix, Brad St; Ho, Mitchell Journal: Antibody therapeutics Issue: Volume 3:Number 1(2020) Page Start: 10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Ancient species offers contemporary therapeutics: an update on shark VNAR single domain antibody sequences, phage libraries and potential clinical applications. (21st January 2020) Authors: English, Hejiao; Hong, Jessica; Ho, Mitchell Journal: Antibody therapeutics Issue: Volume 3:Number 1(2020) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗